by Madaline Spencer | Jul 3, 2026
The US Food and Drug Administration (FDA) has approved Lumvoa (veligrotug) for the treatment of thyroid eye disease (TED), regardless of TED’s duration or activity. TED is a chronic endocrine, autoimmune disease characterized by immune-mediated orbital...
by Madaline Spencer | Jul 2, 2026
Chadi Nabhan, MD, Hematologist and Oncologist, Chief Medical Officer at Ryght AI, and Vivek Subbiah, MD, Professor of Medicine at Stanford University and Executive Medical Director of Novel Therapies & Clinical Trial Network at Stanford Health Care, discuss the...
by Madaline Spencer | Jul 1, 2026
Andrew Kuykendall, MD, Clinical Researcher at Moffitt Cancer Center, discusses the role of rusfertide in decreasing phlebotomies in patients with polycythemia vera (PV). PV is a condition characterized by an increased number of red blood cells. Affected...
by Madaline Spencer | Jun 30, 2026
The US Food and Drug Administration (FDA) has granted full approval to Tecelra (afamitresgene autoleucel; afami-cel) and expanded its indication to include patients ages 12 years and older with unresectable or metastatic synovial sarcoma whose disease has progressed...
by Madaline Spencer | Jun 26, 2026
Eunice S. Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, discusses long-term results of ziftomenib in combination with venetoclax and azacitidine in patients with acute myeloid leukemia (AML). AML is a cancer that affects the...
